Metro International Biotech is developing an extensive portfolio of small-molecule NAD+ precursors that have been shown to increase cellular and mitochondrial NAD+ levels in vivo.
MIB-626 crystallized precursor of NAD+. Metro International Biotech is initially targeting rare mitochondrial diseases, though modulating NAD+ has exhibited broad potential to treat a range of serious conditions and diseases.
MIB-626 crystallized precursor of NAD+
MIB-626 is a proprietary, crystallized precursor of NAD+ optimized for potency, bio distribution, pharmacodynamic and pharmacokinetic properties.
Metro International Biotech has conducted multiple IRB-approved human safety and bioavailability trials at a prominent Boston hospital, which demonstrated MIB-626 is well tolerated in healthy human volunteer subjects and raises blood levels of NAD+ and related metabolites.